• Русский
  • English

Talking about us

14.06.2018 -
Belarus, Uzbekistan to set up joint ventures in pharmaceutics

Uzbekistan is interested in expanding cooperation with Belarus in the pharmaceutical industry. “A roadmap has been signed to set up joint ventures to produce medicines in Uzbekistan. The Nativita company has already established operations in the country. We have good prospects ahead,” Mikhail Myasnikovich said.

Read more
18.05.2018 - BelTA
Belpharmprom, NatiVita to cooperate with Japan’s Chukan Butsu

A partnership agreement was concluded bewteen Belarus’ pharmaceutical company NatiVita and Japan’s Chukan Butsu. Belarus’ Belpharmprom Holding Company signed a memorandum of cooperation with this Japanese company.

Read more
20.04.2018 - BelTA
Belarus’ pharmaceutical capacities on display in Japan

Belarus is showcasing the capacities of its pharmaceutical industry in Japan.

Read more
2.04.2018 -
Plans to set up personified vaccine R&D centers in Belarus, Saint Petersburg

Future R&D cooperation between NatiVita and the Russian biotechnology company Biocad was discussed as Prime Minister of Belarus Andrei Kobyakov visited Saint Petersburg where the tenth session of the Belarus-Saint Petersburg Business Cooperation Council took place. Cooperation between NatiVita and Biocad will proceed within the framework of the research program on exploring personified healthcare technologies, the so-called cell technologies.

Read more
2.04.2018 -
Cooperation with Russian partners helps Belarus reduce price for targeted therapy

Nativita was the first company in Belarus to register targeted drugs, primarily monoclonal antibodies. This became possible thanks to cooperation with Russian counterparts, Biocad. The first stage of technology transfer is underway. This is the packaging and quality control of the product in Belarus.

Read more
19.07.2017 - BelTA
Lithuanian private sector eyeing Belarusian pharmaceutics with interest

The Lithuanian private sector shows a strong interest in the Belarusian pharmaceutics industry, BelTA learned from Linas Valentukevicius, member of the Board of Directors of Avia Solutions Group, member of the Board of Directors of Nativita Company.

Read more
14.07.2017 - BelTA
Belarusian, Cuban scientists working on drugs to bolster immune response to malignant tumors

Belarusian and Cuban scientists are busy researching medications based on peptide vaccines for the sake of immunotherapy of malignant tumors, BelTA learned from Yevgeny Shlyakhtunov, Associate Professor at the Oncology Chair of the Vitebsk State Medical University, Candidate of Medical Sciences, an employee of the R&D and manufacturing complex Nativita.

Read more